Published in Liver Transpl on December 01, 2008
Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis (2013) 4.27
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med (2003) 2.64
Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med (2010) 2.44
Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology (2012) 2.35
Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl (2005) 2.04
Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol (2003) 2.04
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol (2003) 1.90
Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis (2009) 1.83
Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis (2004) 1.71
Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med (2007) 1.69
Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis (2008) 1.58
Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis (2008) 1.58
Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl (2012) 1.53
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr (2007) 1.43
A long-term study of changes in the volume of brain ventricles and white matter lesions after successful liver transplantation. Transplantation (2010) 1.42
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. Liver Transpl (2011) 1.40
[One thousand liver transplants. Hospital Clinic i Provincial de Barcelona (Spain)]. Cir Esp (2005) 1.39
Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis (2002) 1.39
Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART. Enferm Infecc Microbiol Clin (2008) 1.39
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother (2007) 1.30
Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis (2003) 1.24
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr (2009) 1.16
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother (2003) 1.15
Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol (2010) 1.14
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother (2008) 1.14
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS (2005) 1.11
Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transpl (2011) 1.05
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One (2013) 1.05
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS (2012) 1.04
Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis (2011) 1.04
Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.02
Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother (2003) 1.01
The future of antiretroviral therapy: challenges and needs. J Antimicrob Chemother (2010) 1.00
Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg (2001) 0.98
Leishmania infantum DNA detection in urine from patients with visceral leishmaniasis and after treatment control. Am J Trop Med Hyg (2008) 0.97
Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect (2003) 0.96
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS (2003) 0.96
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis (2006) 0.96
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis (2008) 0.95
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. J Antimicrob Chemother (2010) 0.95
Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer. Ann Surg Oncol (2008) 0.95
A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin Cancer Res (2013) 0.94
Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res Hum Retroviruses (2011) 0.94
Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J Antimicrob Chemother (2004) 0.93
Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with leishmania and human immunodeficiency virus. Am J Trop Med Hyg (2005) 0.93
Brain magnetic resonance spectroscopy in episodic hepatic encephalopathy. J Cereb Blood Flow Metab (2012) 0.92
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS (2007) 0.92
Management of tuberculosis in HIV-infected patients. AIDS Rev (2012) 0.92
Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation (2007) 0.91
How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses (2009) 0.91
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol (2005) 0.90
Successful transplantation of organs from a donor with postneurosurgical meningitis caused by Escherichia coli. Transplantation (2012) 0.90
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. Curr HIV Res (2009) 0.89
Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine (2005) 0.89
Increased expression and activity of hepatic lipase in the liver of morbidly obese adult patients in relation to lipid content. Obes Surg (2008) 0.89
Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother (2010) 0.89
Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis (2009) 0.89
Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Opin Pharmacother (2003) 0.89
Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol (2012) 0.88
Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg (2009) 0.88
GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin (2011) 0.88
Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother (2003) 0.87
The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg (2010) 0.87
Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci (2011) 0.87
Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant (2009) 0.87
Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS (2010) 0.87
Incisional surgical site infection in kidney transplantation. Urology (2008) 0.86
Only C-reactive protein, but not TNF-α or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg (2012) 0.86
[Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]. Rev Esp Cardiol (2002) 0.86
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. J Acquir Immune Defic Syndr (2004) 0.86
Full face transplant: the first case report. Ann Surg (2011) 0.86
T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology (2003) 0.86
Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre. Hepatol Int (2010) 0.86
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis (2009) 0.85
Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis (2003) 0.85
Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol (2006) 0.85
Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. AIDS Rev (2011) 0.85
Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort). AIDS (2002) 0.85
From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opin Drug Saf (2011) 0.84
Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 0.84
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis (2012) 0.84
Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. PLoS One (2013) 0.84
Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients. Am J Trop Med Hyg (2013) 0.84
Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg (2010) 0.84
Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl (2002) 0.83
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. J Acquir Immune Defic Syndr (2009) 0.83
Our experience in liver transplantation in patients over 65 yr of age. Clin Transplant (2008) 0.83
Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother (2013) 0.82
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retroviruses (2010) 0.82
Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant (2010) 0.82